NCT07190391View on ClinicalTrials.gov

Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

Not yet recruitingOBSERVATIONAL
Enrollment

425

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

October 31, 2027

Conditions
Psoriasis
Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT07190391 - Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis | Biotech Hunter | Biotech Hunter